ReviewFrontiers in molecular neuroscience2026
Advances in pathogenesis, novel therapeutic strategies and interventions for age-related hearing loss.
Review in Frontiers in molecular neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Age-related hearing loss (ARHL), or presbycusis, represents one of the most prevalent sensory dysfunctions in the elderly people. It is characterized by progressive hearing deterioration that significantly impairs quality of life and increases the risk of comorbidities including cognitive impairment, depression, and social isolation. The pathogenesis of ARHL involves complex structural alterations such as degeneration of cochlear hair cells, loss of spiral ganglion neurons, and stria vascularis atrophy, coupled with molecular and cellular dysregulations including oxidative stress, inflammation, autophagy dysfunction, and cellular senescence. Meanwhile, genetic predisposition and environmental factors contribute to its development. Current conventional management primarily relies on hearing aids, which fail to reverse disease progression, while effective pharmacological interventions remain unavailable. Recent years have witnessed promising developments in innovative approaches such as gene therapy, stem cell-based regenerative medicine, nanotechnology-based delivery systems, and early biomarker screening, offering new directions for precise ARHL intervention. The purpose of this review is to provide a comprehensive overview of the current state of research in ARHL, with the goal of advancing our understanding, treatment and interventions of presbycusis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.